CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment

• The agency said NfL could be used as a marker to predict patient benefit, but more data is still needed to confirm that link.
• Clene plans to submit its NDA in the third quarter of 2026.
• The firm’s CNM-Au8 has demonstrated a favorable safety profile with no serious treatment-related side effects.

Shares of Clene Inc. (CLNN) climbed more than 8% on Monday after a positive update from the U.S. Food and Drug Administration signaled a potentially faster path to approval for its experimental ALS treatment.

CLNN shares traded at their highest levels in 2026.

Clene To Submit NDA By Q3 2026

According to the company, following a recent meeting, the FDA noted that its data, particularly changes in the neurofilament light (NfL) biomarker, may support a New Drug Application (NDA) under the accelerated pathway. The biomarker indicates active damage to nerve cells.

The agency said NfL could be used as a marker to predict patient benefit, but more data is still needed to confirm that link. Clene plans to submit its NDA in the third quarter of 2026.

“We are encouraged by the FDA’s careful evaluation of the benefits and risks associated with Clene’s ALS drug candidate, CNM-Au8, including the biomarker data the company provided. We are committed to working with the Agency on this filing and are conducting the Phase 3 confirmatory study for CNM-Au8, which we intend to commence in the first quarter of 2027,” said Rob Etherington, President and CEO of Clene.

Clene’s experimental ALS drug CNM-Au8 showed strong biomarker and safety results. CNM-Au8 has also demonstrated a favorable safety profile with no serious treatment-related side effects reported.

How Did Retail Traders React?

Retail sentiment for CLNN on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, accompanied by ‘extremely high’ message volumes.

One user said the acceptance of the NDA is near certainty.

Another user said, despite the positive news, “retail investors have yet to grasp its true significance.”

The stock has gained more than 5% so far in 2026.

Read also: Why Did CNSP Stock Surge 330% Today?

For updates and corrections, email newsroom[at]stocktwits[dot]com.